M&A Deal Summary

Meridian Bioscience Acquires Magellan Biosciences

On March 24, 2016, Meridian Bioscience acquired medical products company Magellan Biosciences from Ampersand Capital Partners and NMT Capital

Acquisition Highlights
  • This is Meridian Bioscience’s 4th transaction in the Medical Products sector.
  • This is Meridian Bioscience’s 6th transaction in the United States.
  • This is Meridian Bioscience’s 2nd transaction in Massachusetts.

M&A Deal Summary
Date 2016-03-24
Target Magellan Biosciences
Sector Medical Products
Buyer(s) Meridian Bioscience
Sellers(s) Ampersand Capital Partners
NMT Capital
Deal Type Add-on Acquisition

Target

Magellan Biosciences

Chelmsford, Massachusetts, United States
Magellan Biosciences, Inc. is a developer and manufacturer of FDA-cleared products for the testing of blood to diagnose lead poisoning in children and adults.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Meridian Bioscience

Cincinnati, Ohio, United States
Category Company
Founded 1976
Sector Life Science
Employees702
Revenue 318M USD (2021)
DESCRIPTION

Meridian is a life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Meridian was founded in 1976 and is based in Cincinnati, Ohio.

DEAL STATS #
Overall 7 of 11
Sector (Medical Products) 4 of 5
Type (Add-on Acquisition) 5 of 7
State (Massachusetts) 2 of 2
Country (United States) 6 of 8
Year (2016) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-24 Magellan Diagnostics

North Billerica, Massachusetts, United States

Magellan Diagnostics, Inc. is a medical device company develops and manufactures point-of-care systems clinical laboratory instruments.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-04-30 GenePOC - State-of-the-Art Molecular Diagnostics Platform

Québec, Quebec, Canada

GenePOC, Inc. - State-of-the-Art Molecular Diagnostics Platform provides a sample to result testing for single tests, as well as flexible multiplexing capability.

Buy $120M

Seller(S) 2

SELLER

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1988
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.

DEAL STATS #
Overall 25 of 55
Sector (Medical Products) 7 of 14
Type (Add-on Acquisition) 18 of 38
State (Massachusetts) 5 of 14
Country (United States) 25 of 51
Year (2016) 3 of 9
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-22 Blue Sky BioServices

Worcester, Massachusetts, United States

Blue Sky BioServices is a contract research organization (CRO) that provides gene through screen services in the pharmaceutical and biotechnology R&D market. Blue Sky BioServices was founded in 2003 and is based in Worcester, Massachusetts.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-31 Florida Biologix

Alachua, Florida, United States

Florida Biologix is a provider of biopharmaceutical development, manufacturing, and testing services to the biotechnology industry and to biomedical research institutions.

Sell -
SELLER

NMT Capital

Norwell, Massachusetts, United States
Category Private Equity Firm
Size Small
Type Sector Agnostic
DESCRIPTION

NMT Capital is a private equity firm focused on tech-oriented growth industries. Areas of interest include medical devices, diagnostics, biotechnology, specialty pharmaceutical, drug discovery tools, software, communications, information technology, and advanced materials. NMT Capital is based in Quincy, Massachusetts.

DEAL STATS #
Overall 9 of 10
Sector (Medical Products) 4 of 5
Type (Add-on Acquisition) 8 of 9
State (Massachusetts) 2 of 2
Country (United States) 7 of 8
Year (2016) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-09 Spectra Analysis Instruments

Marlborough, Massachusetts, United States

Spectra Analysis Instruments is the developer and manufacturer of next-generation Molecular Analysis Instrumentation which solves the critical limitations of current Infrared technology being experienced by the life sciences and other industries, in the essential analysis of complex materials.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-03-05 iovera

Fremont, California, United States

MyoScience, Inc. is a medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. MyoScience, Inc. was founded in 2005 and is based in Fremont, California.

Sell $220M
Mergr

Product

Company

Legal